2022
Could Programmed Death-Ligand 1 Copy Number Alterations be a Predictive Biomarker for Immunotherapy Response?
Woodard GA, Cho C, Chen L. Could Programmed Death-Ligand 1 Copy Number Alterations be a Predictive Biomarker for Immunotherapy Response? Journal Of Thoracic Oncology 2022, 17: 592-595. PMID: 35465963, DOI: 10.1016/j.jtho.2022.03.009.Peer-Reviewed Original Research
2020
Activation of p38α stress-activated protein kinase drives the formation of the pre-metastatic niche in the lungs
Gui J, Zahedi F, Ortiz A, Cho C, Katlinski K, Alicea-Torres K, Li J, Todd L, Zhang H, Beiting D, Sander C, Kirkwood J, Snow B, Wakeham A, Mak T, Diehl J, Koumenis C, Ryeom S, Stanger B, Puré E, Gabrilovich D, Fuchs S. Activation of p38α stress-activated protein kinase drives the formation of the pre-metastatic niche in the lungs. Nature Cancer 2020, 1: 603-619. PMID: 34124690, PMCID: PMC8194112, DOI: 10.1038/s43018-020-0064-0.Peer-Reviewed Original ResearchConceptsPre-metastatic nicheFibroblast activation proteinStress-activated protein kinasePrimary tumor-derived factorsActivation proteinDisseminated malignant cellsNormal cellsActivity of p38Tumor-derived factorsExpression of chemokinesActivation of p38αInactivation of p38Subsequent pulmonary metastasesStimulation of expressionType I interferonProtein kinaseLung infiltrationP38 inhibitorAdjuvant therapyMetastatic diseaseP38α kinasePulmonary metastasesLung metastasesPoor prognosisMetastatic cancer
2019
An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles
Ortiz A, Gui J, Zahedi F, Yu P, Cho C, Bhattacharya S, Carbone CJ, Yu Q, Katlinski KV, Katlinskaya YV, Handa S, Haas V, Volk SW, Brice AK, Wals K, Matheson NJ, Antrobus R, Ludwig S, Whiteside TL, Sander C, Tarhini AA, Kirkwood JM, Lehner PJ, Guo W, Rui H, Minn AJ, Koumenis C, Diehl JA, Fuchs SY. An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles. Cancer Cell 2019, 35: 33-45.e6. PMID: 30645975, PMCID: PMC6336114, DOI: 10.1016/j.ccell.2018.12.001.Peer-Reviewed Original ResearchConceptsTumor-derived extracellular vesiclesMelanoma lung metastasisPre-metastatic nicheLung metastasesAdjuvant melanoma therapyAnti-hypertensive drugsUse of reserpineExtracellular vesiclesType I interferon receptorMelanoma patientsPoor prognosisCH25HMelanoma therapyIFN receptorInterferon receptorMetastasisNormal cellsHealthy cellsReceptorsUptakeCellsPatientsPrognosisReserpineTherapy
2016
The fibronectin III-1 domain activates a PI3-Kinase/Akt signaling pathway leading to αvβ5 integrin activation and TRAIL resistance in human lung cancer cells
Cho C, Horzempa C, Jones D, McKeown-Longo PJ. The fibronectin III-1 domain activates a PI3-Kinase/Akt signaling pathway leading to αvβ5 integrin activation and TRAIL resistance in human lung cancer cells. BMC Cancer 2016, 16: 574. PMID: 27484721, PMCID: PMC4970220, DOI: 10.1186/s12885-016-2621-6.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Non-Small-Cell LungCaspase 8Cell Line, TumorCell SurvivalDrug Resistance, NeoplasmFibronectin Type III DomainFibronectinsGene Expression Regulation, NeoplasticHumansLung NeoplasmsPhosphatidylinositol 3-KinasesProtein FoldingProto-Oncogene Proteins c-aktReceptors, VitronectinSignal TransductionTNF-Related Apoptosis-Inducing LigandVitronectinConceptsType III domainLung cancer cellsUnfolded domainsTRAIL resistancePI3-kinase/AktSerine/threonine kinase pathwaysCancer cellsMulti-modular proteinThreonine kinase pathwaysNCI-H460 lung cancer cellsFnIII-1cFirst Type III domainNon-small cell lung cancer cellsTRAIL-induced apoptosisΑvβ5 integrin receptorLung cancer resistanceCell lung cancer cellsHuman lung cancer cellsKinase pathwayCancer cell resistanceIntegrin activationCaspase-8Signaling pathwaysFibronectin matrixSensitive proteins